Guidelines for primary prevention of cardiovascular disease (CVD) with statins, including the most recent, fail to make the best use of the evidence from clinical trials by concentrating on absolute CVD risk as a statin indication and not also considering that a major determinant of therapeutic benefit is the magnitude of the low-density lipoprotein (LDL) (or non-HDL) cholesterol reduction achieved. This decrease is proportional to the pretreatment concentration. We set out to apply this knowledge to the calculation of the number needed to treat to prevent one event (NNT) and to assess critically how current guidelines performed at different degrees of CVD risk across a range of LDL (or non-HDL) cholesterol concentrations.
Introduction
The major indication for prescribing statins for the prevention of atherosclerotic cardiovascular disease (CVD) in current clinical guidance is absolute CVD risk. 1 -6 A 10-year CVD risk, comprising coronary heart disease and stroke, of ≥20 per 100 (often stated as ≥20%) has until recently been adopted in the UK 4 as the indication for statin treatment based on National Institute for Health and Care Excellence (NICE) recommendations, 1 sometimes referred to as the high-risk strategy. In the rest of Europe and the USA, indications were broadly similar. 2, 3 The problem with these recommendations is that, because the average 10-year CVD risk in the general population is ,20%, the majority of people destined to suffer from CVD will be excluded from primary prevention and thus not receive statin treatment until after the event, assuming they survive it. This is the so-called Rose effect which states that the group in whom most CVD occurs will be those at typical risk, simply because they are more numerous than those at higher risk. 7 Recently, therefore, it has been advocated in the USA that the 10-year CVD risk threshold for the introduction of statin treatment be decreased to 7.5% 5 , and in the UK to 10%. 6 That statins are effective at these levels of risk is supported by evidence from randomized, placebo-controlled, clinical trials. 5, 6 However, the revised guidance has proved controversial, because many more people would receive statin treatment when without it they will not experience CVD and thus they are exposed to its possible adverse effects with nothing to gain. The degree of likelihood of statin side effects occurring in clinical practice as opposed to clinical trial settings has been hotly disputed. 8 Serious statin intolerance is probably rare, 9 but the perception of many apparently healthy people increasingly offered statin treatment that they have experienced side effects and their resentment of medicalization are a significant additional demand on medical resources over and above the cost of the statin itself. 10 In the management of hypertension or diabetes, the height of blood pressure or blood glucose, respectively, is the major determinant of whether a patient receives treatment and its intensity. We question why this is not the case for much of the treatment of hypercholesterolaemia?
In this article, we calculate the number of people needing to be treated to prevent a CVD event with intervention at different degrees of CVD risk and pretreatment cholesterol levels. This raises some important issues about strategies currently being promoted for the clinical deployment of statins, which take little account of the severity of the hypercholesterolaemia and the huge variation in individual benefit possible with statin treatment.
The low-density lipoprotein cholesterol response depends on the choice of statin, its dose, and the pretreatment low-density lipoprotein cholesterol concentration
The low-density lipoprotein cholesterol (LDL-C) concentration response to statins varies from statin to statin and is dose related 6, 12 ( Figure 1) . It is also proportional to the pretreatment LDL-C concentration, something which has not been fully taken into account in recent statin recommendations. 5, 6 Thus, atorvastatin 20 mg daily currently recommended as first-line treatment in primary prevention 5, 6 typically produces a 43% reduction in LDL-C concentration. 6 Therefore, in someone whose LDL-C before treatment is 5 mmol/L, the expected decrease is 2.15 mmol/L, whereas in someone with an initial LDL-C of 3 mmol/L, the decrease will be only 1.29 mmol/L.
How to calculate cardiovascular disease risk reduction taking into account both pretreatment cardiovascular disease risk and low-density lipoprotein cholesterol response
The Cholesterol Treatment Trialists' (CTT) meta-analysis showed that overall each 1 mmol/L reduction in LDL-C resulted in a 22% proportional decrease in the risk of CVD. 11 It was concluded that each 1 mmol/L reduction in LDL-C was associated with a decrease in CVD risk to 0.78 of that in the control group (placebo or less intensively treated) with its hazard ratio of 1. Thus, a 2 mmol/L reduction reduces risk by 40% (since the combination of risk ratios of 0.78 × 0.78 yields a risk ratio of 0.6) and a 3 mmol/L reduction could reduce the risk by 50% (0.78 3 ). In mathematical terms, the decrease in CVD risk should be 0.78 to the power of the LDL-C reduction in mmol/L or 0.78
. This gives a curvilinear model (see Discussion):
where 1 ¼ the number of CVD events prevented per 100 people treated for 10 years and n ¼ LDL-C decrease in mmol/L; *% over next 10 years. For example, if CVD risk is 10% over the next 10 years and LDL-C is lowered by 2 mmol/L, the number of CVD events prevented per 100 people treated for 10 years (1) is (1 -0.78
2 ) × 10 ¼ 3.9.
The number needed to treat for 10 years to prevent one CVD event (NNT) is calculated by dividing by 100 1. The NNT is thus given by 100 / 1, which in the above example would be 26.
The NNT can be calculated from an observed 1 or estimated from the dose -response of a particular statin and the CVD risk predicted for an individual patient by risk engines such as QRISK2 13 or Lloyd-Jones Framingham 14 as recommended by the International Atherosclerosis Society. 15 Some examples of this using QRISK2 are presented in Box 1, but any risk prediction engine providing CVD endpoints similar to the CTT meta-analysis can be used. The application of the NNT is further explained in the next section. If CVD risk prediction engines are to be used in primary prevention, patients with monogenic familial hypercholesterolaemia should be excluded, because such methods under-estimate CVD incidence.
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Applying the number needed to treat to prevent one event and low-density lipoprotein cholesterol response to clinical recommendations
As stated earlier, atorvastatin 20 mg daily currently recommended as first-line treatment in primary prevention 5, 6 typically produces a 43% reduction in LDL-C concentration. 6 Therefore, in someone whose LDL-C before treatment is 5 mmol/L, the expected decrease is 2.15 mmol/L, whereas in someone with an initial LDL-C of 3 mmol/L, the decrease will be only 3, 6 regard each of these people as equally important to treat with a statin, because their CVD risk is similar. In the USA, there is an option to treat simply on the basis of the LDL-C level when this is 4.9 mmol/L or higher. 2, 6 However, this also produces anomalies by not taking into account the CVD risk, as can be seen from the foregoing example of the individual with the higher LDL-C of 5 mmol/L. Thus, two people whose LDL-C is 5 mmol/L, one of whom has a CVD risk of 5% and the other 10% will ively. None of the recommendations allow both the absolute CVD risk and the LDL-C to be used simultaneously in deciding who should receive statin therapy. Currently, the indication for statin treatment is based on an assessment of CVD risk. In the USA and UK, CVD risk embraces both fatal and non-fatal coronary and cerebral ischaemic events. In the USA, initiation of statin treatment is recommended when the 10-year CVD risk is 7.5% or more 6 and in the UK when it is 10% or greater. 6 These have replaced earlier recommendations not to treat until the 10-year CVD risk reached 20%. 1, 2 In Europe as a whole, the most recent guidance remains to initiate statin treatment at approximately this level of CVD risk, because it is based on an estimation of fatal CVD risk of 5% over 10 years, which is equivalent to a 15 -20% combined CVD mortality and morbidity as used in the USA and UK. 3, 16 The NNT for different degrees of LDL-C reduction at these treatment thresholds are presented in Table 1 , assuming the use of atorvastatin 20 mg daily currently recommended as first-line treatment in primary prevention. 5, 6 This typically produces a 43% reduction in LDL-C concentration. 6 The vertical columns in Table 1 illustrate the well-known effect of pretreatment CVD risk on the benefit derived from statin treatment, but horizontally an obvious additional benefit is seen with increasing pretreatment LDL-C. This is so much so that an NNT of around 30 is achieved in people with a 10-year CVD risk of 7.5% only when their pretreatment LDL-C is 5 -6 mmol/ L, whereas similar NNTs occur with pretreatment LDL-C levels of 3 -4 mmol/L in those with a 10% 10-year CVD risk. It is questionable whether treating .30 people for 10 years to prevent one CVD event is really worthwhile for either the patient or the clinical service, particularly in older people in whom competing causes of death and morbidity are prevalent. On the other hand, treating people at any age with higher cholesterol and/or higher CVD risk (as in secondary prevention or diabetes) would appear very worthwhile. Table 2 shows similar calculations of the NNT for varying pretreatment non-high-density lipoprotein (HDL) cholesterol levels rather than LDL-C (see Discussion for method of calculation). It is evident that similar conclusions to those for LDL-C apply. Figures in parentheses are the changes in LDL cholesterol concentration. At pretreatment LDL cholesterol levels higher than 5.5 mmol/L, adjunctive cholesterol-lowering medication will generally be required to hit the target, because maximum dose atorvastatin at 80 mg daily lowers LDL cholesterol by a mean of 55%. 6 LDL, low-density lipoprotein; NNT, number needed to treat to prevent one event.
Number needed to treat to prevent one event and the abandonment of therapeutic goals for low-density lipoprotein (or non-high-density lipoprotein) cholesterol
Both the proposed new guidance in the USA and from NICE 5, 6 would abandon LDL-C treatment goals. Currently, in primary prevention these are 2.5 mmol/L (100 mg/L) in Europe, 3 which is in agreement with the earlier goal in the USA. 2 Tables 3 and 4 , the logical assumption has been made that statin doses will, if necessary, be titrated upwards to achieve their therapeutic targets. It can be seen that the goals disadvantage people with lower pretreatment cholesterol levels whose NNTs are substantially higher in Tables 3 and 4 than they are in Tables 1 and 2 . However, patients with higher pretreatment LDL (or non-HDL) cholesterol derive considerably more benefit in terms of the NNT from reaching therapeutic goals with, if necessary, uptitration of statin doses.
Ezetimibe alone in statin-intolerant patients
Ezetimibe can be tried when patients cannot tolerate statins. It has a single dose regimen of 10 mg daily which decreases LDL-C by 19%. 17 Table 5 reveals that ezetimibe monotherapy has little clinical efficacy in terms of the NNT unless the CVD risk is higher than 10% over the next 10 years and is combined with high pretreatment LDL-C levels. Thus, as with statins, the pretreatment LDL-C is also important in determining the likelihood of benefit.
Discussion
Calculation of the NNT by the clinician would provide a more discriminating method of assisting in the decision as to whether to prescribe statin treatment and avoid exposure of patients, who can derive nugatory benefit from such treatment, to its potential side Figures in parentheses are the changes in LDL cholesterol concentration. At pretreatment LDL cholesterol levels higher than 4 mmol/L, adjunctive cholesterol-lowering medication will generally be required to hit the target, because maximum dose atorvastatin at 80 mg daily lowers LDL cholesterol by a mean of 55%. 6 LDL, low-density lipoprotein; NNT, number needed to treat to prevent one event.
. effects. We report here that people at similar absolute CVD risk vary widely in the extent to which they can benefit from statin treatment depending on the degree to which their LDL-C can be decreased. It would be a very simple matter to add the mathematical terms necessary to take account of this to the computer programs currently recommended for the estimation of CVD risk in clinical practice. Furthermore, use of the NNT would obviate much of the difficulty in trying to deploy statins to younger people with a high lifetime risk of CVD, who might otherwise die needlessly while waiting to reach a threshold for the introduction of a statin, such as a 10-year CVD risk of 10%. Take, for example, someone who is 40 years old with a CVD risk of 5% in the next 10 years, whose LDL-C is 6 mmol/L. Calculation of the NNT reveals that treating such a patient would be more effective than many older people with lower LDL-C levels: in this case, the NNT to prevent one CVD event with atorvastatin 20 mg daily is 42 ( Table 1) , which is similar to an older person with a higher risk of 10%, but a pretreatment LDL-C of 3 mmol/L. It is illogical to treat this patient, but not the younger one.
The results of our calculation of NNTs provide clear support for abolishing the LDL-C goals for statin treatment in people with lower pretreatment LDL levels, but high CVD risk. However, people with more marked hypercholesterolaemia derive more benefit from treatment aimed at specific LDL-C targets. Furthermore, targets are necessary pragmatically in order to judge whether the LDL-C concentration response to statin therapy is adequate. Our findings reveal that the maximum benefit is achieved in the case of atorvastatin 20 mg daily by making the aim of treatment to lower LDL-C by 43% [or non-HDL cholesterol (non-HDL-C) by 40% as currently recommended by NICE 6 ], if this produces a value of ,1.8 mmol/L. If not, the dose should be increased to achieve this target when possible. This translates into a 'fire and forget' policy for those with initial LDL-C levels below 3 mmol/L and dose titration in those with higher starting levels.
Atorvastatin 80 mg daily typically lowers LDL-C by 55%. 6 This means that a target LDL-C concentration of 1.8 mmol/L or less can generally be reached only in people whose pretreatment level is no more than 4 mmol/L. The addition of ezetimibe 10 mg daily to atorvastatin 80 mg daily permits a further decrease in LDL-C of on average 19%. 17 This increases the pretreatment LDL-C level, which can be lowered to the goal of 1.8 mmol/L or less, to around 4.9 mmol/L. We showed, however, that ezetimibe alone in, for example, people who can tolerate no statin has poor NNTs unless both CVD risk and pretreatment LDL-C are high. This will appear counter-intuitive to many clinicians who, because it is less potent than most statins, regard this agent as suitable for patients with modest hypercholesterolaemia. There is, thus, a need for the development of new potent LDL-C lowering medication both for high-risk patients at the bottom end of the LDL-C concentration range, who can tolerate no statins, as well as for adjunctive therapy to add to high-dose potent statin treatment in those with high initial concentrations. Non-high-density lipoprotein cholesterol does not require fasting for its measurement and may be a more discriminating prognostic indicator than LDL-C. 18 Thus, its use in the clinic is increasingly being advocated. 5, 6 Translating the huge body of evidence that has grown up around LDL-C to non-HDL-C, for example to permit the calculation of NNTs for people with various starting levels, is not straightforward. In Robinson et al. 19 and the Third Joint British Societies' (JBS3) report, 20 the statin-induced decrease in CVD risk with lowering of non-HDL-C was estimated erroneously by assuming incorrectly that there is a constant ratio between LDL and non-HDL-C of 1.24 throughout the range of LDL-C. To calculate the reduction in CVD risk with decreases in non-HDL-C on statin treatment in JBS3, the 22% risk reduction that occurs with each 1 mmol/L lowering of LDL-C was divided by 1.24 to obtain a decrease of 18%. 20 This may be reasonably accurate for the first 1 mmol/L decrease in non-HDL-C when the initial level is 3 -4 mmol/L, 19 but not over the range of pretreatment levels and concentration responses encountered in clinical practice. The difference between LDL and non-HDL-C is the cholesterol associated with triglyceride-rich lipoproteins [mostly very low-density lipoprotein (VLDL) cholesterol], which is much more influenced by triglyceride levels than by LDL-C. 21 Very low-density lipoprotein cholesterol can be calculated from the triglyceride level. This has generally been done by assuming that the ratio between serum triglyceride and cholesterol in VLDL is 2.2 (or 5 if mg/dL rather than mmol/L are used). 22 Recently, a series of values for this ratio depending on triglyceride and non-HDL-C levels have been published based on a large population study. 21 We have used these values to calculate the equivalent LDL-C levels for a series of pretreatment non-HDL-C values and to estimate the NNTs at different degrees of CVD risk when atorvastatin 20 mg daily is prescribed ( Table 2 ). Figure 2 shows graphically the curvilinear relationship between the NNT and pretreatment non-HDL-C levels which is modulated by absolute CVD risk and by the statin selected and its dose (in this example atorvastatin 20 mg daily, which lowers LDL-C by 43% 6 ).
The typical non-HDL-C change equivalent to a 43% LDL-C decrease ranged from 38.1% at non-HDL-C of 2 mmol/L to 41.2% at Figure 2 The number needed to treat to prevent one event with atorvastatin 20 mg daily as a function of pretreatment non-high-density lipoprotein-C at a cardiovascular disease (CVD) risk of 5 -20% over the next 10 years. HDL, high-density lipoprotein; NNT, number needed to treat to prevent one event.
7 mmol/L. Non-HDL-C was introduced in the USA as a statin target in hypertriglyceridaemia when LDL-C could not be easily measured. 23 The non-HDL targets were set 0.78 mmol/L (30 mg/dL) higher than their equivalent LDL-C goals. However, VLDL cholesterol concentrations of 0.78 mmol/L would be exceptional in people with serum triglyceride in the normal range. So, if non-HDL is to be adopted generally as a statin target, 6, 20 it should be recognized that it will be closer to the LDL-C.
In the present investigation, we have employed a curvilinear model for the calculation of the decrease in the frequency of CVD events with cholesterol lowering. Previously, 16 we have described the use of a simple linear function for the same purpose [CVD events prevented per 100 people treated for 10 years (1) ¼ 0.22 × decrease in LDL-C × CVD risk]. Grundy in 1998 proposed that the decrease in CVD risk might relate to the extent of LDL-C lowering 24 in either a linear or a curvilinear fashion. In epidemiology, because CVD risk is an exponential function of LDL-C, 25 a curvilinear decline in CVD risk with LDL-C lowering might be anticipated. However, the observed CVD risk reduction 11 in 26 randomized clinical trials ( Figure 3 ) cannot be confidently said to depart from linearity and, if it is curved, is certainly more moderately so than the epidemiological relationship in which the CVD risk declines by 50% with each mmol/L decrease in LDL-C in people aged 40 -69 years. 25 Thus, the linear and curvilinear methods produce results that differ little (see Supplementary material online, Table S1 ). For LDL-C reductions of ,1 mmol/L, the NNTs by the curvilinear model are slightly lower than by the linear model and for LDL-C responses .1 mmol/L they are a little higher. For example, at a 10-year CVD risk of 10%, the NNT with atorvastatin 20 mg daily with pretreatment LDL-C 2 mmol/L is 60 by the linear approach and 58 by the curvilinear estimate. For a pretreatment LDL-C of 7 mmol/L, the NNT by the linear equation is 16 and by the curvilinear model is 20. Conclusions about the extent to which statin-induced decreases in LDL-C concentration influence clinical benefit are thus similar by both methods and challenge some of the recent recommendations with equal force. The economic aspects of the guidelines can be assessed using NNTs. The earlier advice from NICE was a 20% 10-year risk threshold for the introduction of statin therapy. 1 At this degree of risk, the NNT to prevent one CVD event would be 19. This assumes a decrease in LDL-C in people whose LDL-C was 3.7 mmol/L (the mean for the UK from middle age onwards 26 ) using simvastatin 40 mg daily (the previously recommended first-line statin 1 ), which would typically result in a decrease in LDL-C of 1.2 mmol/L. 27 Cholesterol, not just cardiovascular risk 20 mg daily, which lowers LDL-C by 43%. 6 If that person's LDL-C Ideally the NNT for statin treatment could be set against the number needed to harm (NNH) both in counselling individuals and in developing a strategy to achieve overall benefit in populations at specific degrees of CVD risk. Results of randomized, typically placebo-controlled clinical trials are used in this report to estimate the NNT. Evidence of harmful effects of statins from placebocontrolled trials would indicate that a huge number of people must receive statins for one case with a serious side effect to emerge. 9, 11 The vicissitudes of clinical practice will make side effects, such as myositis, genuinely attributable to statin treatment more frequent than in clinical trials. The difficulty is to obtain unbiased estimates of this. Studies based on non-randomized general practice databases, in which the non-statin users were not asked to report symptoms similar to those of possible statin side effects nor were they monitored similarly biochemically, must inevitably overestimate adverse statin effects. 9, 10 Numbers needed to harm of 91 and 259 for myositis in men and women, respectively, were reported in new statin users followed for 5 years. The frequency of symptoms attributed to statins declines with time and so it is unlikely that these rates should be doubled for 10 years of exposure. Even so, our present report shows that NNH from this source cannot be considered to counteract beneficial statin NNTs except perhaps in people with low LDL-C levels closest to the CVD risk threshold for statin treatment in primary prevention. This is even more evident if the degree of harm caused by statin treatment is compared with that from withholding treatment. Whereas the great majority of statin side effects are reversible, this is not the case for CVD events preventable by statin therapy, including death and cardiac failure, which are irreversible and necessitate expensive interventions and drug treatment. More work needs to be done to establish credible estimates of the rates of serious statin side effects in the community.
Further research into the use of the NNT to assist the clinical decision to prescribe statins should involve practical assessment of how helpful it is to clinicians and patients and comparison of decision-making and outcomes based only on CVD risk and with the NNT in addition in populations followed prospectively, like that recently undertaken to compare US and European guidelines in the Rotterdam Heart Study. 29 
Conclusion
In conclusion, the NNT for statin therapy, and thus its potential benefit, is clearly influenced by the pretreatment LDL-C concentration. Guidelines should adopt the NNT as a means of aiding the clinical decision to introduce statin treatment in individual patients. Abolishing the LDL therapeutic goals benefits people with lower pretreatment LDL levels. However, people with more marked hypercholesterolaemia derive more benefit from treatment aimed at specific targets.
